Venture(US:VEMLY) Sou Hu Cai Jing·2025-12-12 03:00Group 1 - The launch of the National Medical Insurance Administration's drug price registration system reflects a strong support for pharmaceutical innovation and development, helping companies build a global drug pricing system and modernize drug price governance [1] - The system operates on the principle of "one location for acceptance, nationwide sharing, and global openness," providing drug price registration and inquiry services for domestic and foreign pharmaceutical companies, facilitating the internationalization of Chinese innovative drugs and attracting high-quality foreign drugs to the Chinese market [1] - The importance of China's large-scale market in the global pharmaceutical landscape is increasing, raising higher demands for improving the drug price governance system, with signs of recovery in the supply and demand sides of the pharmaceutical industry [1] Group 2 - The ChiNext Medical ETF (159377) tracks the Innovation Medicine Index (399275), which saw a daily fluctuation of 20%, selecting listed companies from the pharmaceutical and biotechnology sectors, focusing on high-growth and innovative companies in the healthcare field [1]